Crispr Therapeutics AG vs iShares TIPS Bond ETF — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.99B), while iShares TIPS Bond ETF trades at $107.99. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRSP | TIP | |
|---|---|---|
Market Cap | $4.99B | — |
Sector | Health | Fixed Income |
52-Week High | $76.78 | $112.20 |
52-Week Low | $44.34 | $107.91 |
Enterprise Value | $3.33B | — |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →